Chimerix Announces TEMBEXA Procurement Agreement for Approximately $25.3 Million with Public Health Agency of Canada
24 juin 2022 10h06 HE
|
Chimerix, Inc.
DURHAM, N.C., June 24, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of...
Chimerix Announces $9.3 Million International TEMBEXA Procurement Agreement
23 juin 2022 09h15 HE
|
Chimerix, Inc.
DURHAM, N.C., June 23, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of...
Chimerix to Present at Jefferies Global Healthcare Conference
01 juin 2022 16h30 HE
|
Chimerix, Inc.
DURHAM, N.C., June 01, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of...
Chimerix to Present at H.C. Wainwright Global Investment Conference
17 mai 2022 16h15 HE
|
Chimerix, Inc.
DURHAM, N.C., May 17, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients...
Chimerix Reports First Quarter 2022 Financial Results and Provides Operational Update
16 mai 2022 07h00 HE
|
Chimerix, Inc.
– Receiving up to $337.5 Million plus Royalties for Sale of Worldwide Rights of TEMBEXA to Emergent BioSolutions – – Initiation of Phase 3 Randomized Study of ONC201 in H3 K27M Mutant Glioma Expected...
Chimerix Announces Sale of TEMBEXA to Emergent BioSolutions for up to $337.5 Million plus Royalties
16 mai 2022 06h30 HE
|
Chimerix, Inc.
– $225 Million in Upfront Proceeds Secures Substantial Capital to Fund Operations and Allows for Participation in Future Economics – – Transaction Allows for Focus on Development Pipeline – –...
Chimerix to Participate in Maxim Group Panel Discussion
12 mai 2022 16h15 HE
|
Chimerix, Inc.
DURHAM, N.C., May 12, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients...
Chimerix to Report First Quarter 2022 Financial Results and Provide an Operational Update on May 16, 2022
09 mai 2022 07h00 HE
|
Chimerix, Inc.
DURHAM, N.C., May 09, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients...
Chimerix to Present at Maxim Group 2022 Virtual Growth Conference
21 mars 2022 07h00 HE
|
Chimerix, Inc.
DURHAM, N.C., March 21, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
Chimerix Reports Fourth Quarter and Year End 2021 Financial Results and Provides Operational Update
01 mars 2022 07h00 HE
|
Chimerix, Inc.
– TEMBEXA RFP Response Submitted and Under Review with BARDA – – Pre-Clinical CMX521 Data Accepted for Late Breaking Oral Presentation at International Conference on Antiviral Research – – ONC201...